PMID- 22742083
OWN - NLM
STAT- MEDLINE
DCOM- 20130716
LR  - 20221207
IS  - 1753-0407 (Electronic)
IS  - 1753-0393 (Print)
IS  - 1753-0407 (Linking)
VI  - 4
IP  - 4
DP  - 2012 Dec
TI  - Safety, tolerability, and efficacy of metformin extended-release oral 
      antidiabetic therapy in patients with type 2 diabetes: an observational trial in 
      Asia.
PG  - 395-406
LID - 10.1111/j.1753-0407.2012.00220.x [doi]
AB  - BACKGROUND: The aim of the present prospective observational study was to assess 
      the tolerability and antihyperglycemic efficacy of metformin extended-release 
      (MXR) in the routine treatment of patients with type 2 diabetes mellitus (T2DM) 
      from six Asian countries. METHODS: Data from 3556 patients treated with 
      once-daily MXR for 12 weeks, or until discontinuation, were analyzed. RESULTS: 
      Treatment with MXR was well tolerated, with 97.4% of patients completing 12 weeks 
      of treatment. Only 3.3% of patients experienced one or more gastrointestinal (GI) 
      side-effects and only 0.7% of patients discontinued for this reason (primary 
      endpoint). The incidence of GI side-effects and related discontinuations appeared 
      to be considerably lower during short-term MXR therapy than during previous 
      treatment (mean 2.71 years' duration), most commonly with immediate-release 
      metformin. A 12-week course of MXR therapy also reduced HbA1c and fasting glucose 
      levels from baseline. CONCLUSIONS: The present study provides new insights into 
      the incidence of GI side-effects with MXR in Asian patients with T2DM and on the 
      tolerability of MXR in non-Caucasian populations. Specifically, these data 
      indicate that once-daily MXR not only improves measures of glycemic control in 
      Asian patients with T2DM, but also has a favorable GI tolerability profile that 
      may help promote enhanced adherence to oral antidiabetic therapy.
CI  - (c) 2012 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley 
      Publishing Asia Pty Ltd.
FAU - Kim, Chul-Hee
AU  - Kim CH
AD  - Soonchunhyang University Bucheon Hospital, Gyeonggi-do, Seoul, Korea.
FAU - Han, Kyung-Ah
AU  - Han KA
FAU - Oh, Han-Jin
AU  - Oh HJ
FAU - Tan, Kevin Eng-Kiat
AU  - Tan KE
FAU - Sothiratnam, Radhakrishna
AU  - Sothiratnam R
FAU - Tjokroprawiro, Askandar
AU  - Tjokroprawiro A
FAU - Klein, Marcus
AU  - Klein M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Asia
MH  - Asian People
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/ethnology/metabolism
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/pharmacokinetics/therapeutic use
MH  - Male
MH  - Metformin/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
PMC - PMC3549486
EDAT- 2012/06/30 06:00
MHDA- 2013/07/17 06:00
CRDT- 2012/06/30 06:00
PHST- 2012/06/30 06:00 [entrez]
PHST- 2012/06/30 06:00 [pubmed]
PHST- 2013/07/17 06:00 [medline]
AID - 10.1111/j.1753-0407.2012.00220.x [doi]
PST - ppublish
SO  - J Diabetes. 2012 Dec;4(4):395-406. doi: 10.1111/j.1753-0407.2012.00220.x.